Global Overactive Bladder Treatment Market 2018-2028

過活動膀胱治療の世界市場

◆タイトル:Global Overactive Bladder Treatment Market 2018-2028
◆商品コード:VGN808053
◆調査・発行会社:visiongain
◆発行日:2018年6月
◆ページ数:298
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用)GBP2,699 ⇒換算¥410,248見積依頼/購入/質問フォーム
Five User(5名様閲覧用)GBP2,999 ⇒換算¥455,848見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)GBP4,999 ⇒換算¥759,848見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

visiongain社が発行した当調査レポートでは、過活動膀胱治療の世界市場について調査・分析し、過活動膀胱治療の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。

The global ophthalmic drugs market is expected to grow at a CAGR of 4.4% in the first half of the forecast period. The market is expected to grow at a CAGR of 4.8% from 2017-2028. The market is estimated at $24bn in 2017, dominated by the retinal disorder drugs segment.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 298-page report you will receive 123 tables and 113 figures– all unavailable elsewhere.

The 298-page report provides clear detailed insight into the global ophthalmic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Ophthalmic Drugs market forecasts from 2017-2028

• This report also breaks down the revenue forecasts to 2028 for the global ophthalmic drugs market by the leading submarkets:
• Retinal Disorder Drugs
• Allergic, Inflammatory & Infective Drugs
• Glaucoma Drugs
• Dry Eye Drugs
• Other Ophthalmic Drugs

• This report includes revenue forecasts to 2028 for the following ophthalmic drugs:
• Eylea
• Lucentis
• Avastin
• Visudyne
• Jetrea
• Pataday
• Vigamox
• Patanol
• TobraDex
• Cravit
• AzaSite
• Acular
• Lumigan and Ganfort
• Xalatan/Xalacom
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
• Azopt
• Trusopt
• Zioptan
• Cosopt
• Tapros/Taflotan
• Restasis
• Refresh
• Hyalein
• Diquas

Global Ophthalmic Drugs Market Forecast 2018-2028

• This report provides individual revenue forecasts to 2028 for these national markets:
• The US
• Japan
• EU5: Germany, France, the UK, Spain, Italy
• Russia
• China
• India
• Brazil
• Rest of the World

• Our study provides a SWOT analysis and discusses Porter’s Five Forces analysis that influence the global ophthalmic drugs market

• Our report provides discussion on the ophthalmic drugs that are currently in the development pipeline

• Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:
• Novartis
• Regeneron
• Allergan
• Roche
• Valeant
• Santen
• Bayer
• Pfizer
• Senju

Visiongain’s study is intended for anyone requiring commercial analyses for the global ophthalmic drugs market. You find data, trends and predictions.

Buy our report today Global Ophthalmic Drugs Market Forecast 2018-2028: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs.

【レポートの目次】

1. Report Overview

1.1 Global Ophthalmic Drugs: Market Overview

1.2 Global Ophthalmic Drugs Market Segmentation

1.3 Why You Should Read This Report

1.4 How This Report Delivers

1.5 Key Questions Answered by This Analytical Report

1.6 Who Is This Report For?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Reports

1.10 About Visiongain

2. An Introduction to Ophthalmic Drugs

2.1 The Pharmaceutical Industry: A Brief Introduction

2.1.1 Ophthalmic Treatments – An Industry Overview

2.2 The Human Eyes – Structurally Delicate and Functionally Intricate Organs

2.3 The Global Burden of Eye Disease

2.4 Ophthalmic Drugs: Market Segmentation

2.5 Glaucoma: A Major Cause of Vision Loss

2.5.1 A Classification of Glaucoma

2.5.1.1 Primary Open-Angle Glaucoma

2.5.1.2 Acute Angle-Closure Glaucoma

2.5.1.3 Congenital Glaucoma

2.5.1.4 Secondary Glaucoma

2.5.1.5 Normal-Tension Glaucoma

2.5.1.6 Ocular Hypertension

2.5.2 Risk Factors for Glaucoma

2.5.3 Diagnosis of Glaucoma

2.5.4 Drug Treatment of Glaucoma

2.5.5 Laser Treatment and Surgery for Glaucoma

2.6 Age-Related Macular Degeneration (AMD)

2.6.1 Dry (non-exudative) AMD

2.6.2 Wet (exudative) AMD

2.6.3 Risk Factors for AMD

2.6.4 Diagnosis of AMD

2.6.5 Treatment of AMD

2.7 Diabetic Retinopathy (DR)

2.7.1 Diagnosis of Diabetic Retinopathy

2.7.2 Risk factor of Diabetic Retinopathy

2.7.3 Treatment of Diabetic Retinopathy

2.8 Ocular Allergy and Allergic Conjunctivitis

2.8.1 Diagnosis of Ocular Allergy

2.8.2 Treatment of Ocular Allergy

2.9 Ocular Inflammatory Disease

2.9.1 Risk factors of Ocular Inflammatory Disease

2.9.2 Treatment of Ocular Inflammatory Disease

2.10 Eye Infections

2.10.1 Treatment of Eye Infections

2.11 Dry Eye Syndrome

2.11.1 Treatment of Dry Eye Syndrome

2.12 Phases of Clinical Trials

2.13 Ophthalmic Drugs: Market Definition in This Report

3. The Global Ophthalmic Drugs Market, 2017-2028

3.1 The Global Ophthalmic Drugs Market: Market Overview

3.2 Categorisation of the Global Ophthalmic Drugs Market

3.3 The Global Ophthalmic Drugs Market In 2017

3.4 The Global Ophthalmic Drugs Market: Market Forecast 2017-2028

3.5 Ophthalmic Drugs: Changing Market Shares by Sector 2017-2028

4. The Retinal Disorder Drugs Market: Market Analysis and Forecast 2017-2028

4.1 Leading Products in the Retinal Disorder Drugs Market, 2017

4.2 Retinal Disorders: Market Trends and Developments, 2016

4.2.1 The Rise of Eylea

4.2.2 The Debate Around Off-Label Avastin Use and The Role of Novartis And Roche

4.2.3 How Likely Is Avastin’s Expansion into Age-Related Macular Degeneration?

4.2.4 Jetrea: Underwhelming Sales Cause ThromboGenics to Switch Focus to Their Pipeline

4.2.5 Drug/Device Combination Products Entering the Market

4.2.6 Does Regenerative Medicine Have a Successful Future in Ophthalmics?

4.3 Retinal Disorder Drugs: Market Forecast 2017-2028

4.3.1 Retinal Disorder Drugs: Changing Market Shares by Leading Drugs 2017-2028

4.4 Leading Drugs for The Treatment of Retinal Disorders

4.5 Eylea (aflibercept) – Regeneron/ Bayer/ Santen

4.5.1 Recent Approvals for Eylea

4.5.2 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?

4.5.3 Eylea: Sales Forecast 2017-2028

4.5.4 Possible Combination Therapies Involving Eylea

4.6 Lucentis (ranibizumab) – Roche/ Novartis

4.6.1 Lucentis: Sales Forecast 2017-2028

4.6.2 Less Frequent Dosing Approved in US for Lucentis

4.6.3 New Indications for Lucentis

4.6.4 Possible Combination Therapy Involving Lucentis

4.7 Avastin (bevacizumab) – Roche

4.7.1 Avastin: Sales Forecast 2017-2028

4.7.2 Compounding Pharmacies and Safety Risks

4.8 Visudyne (verteporfin) – Valeant/ Novartis

4.8.1 Visudyne: Sales Forecast 2017-2028

4.9 Jetrea (ocriplasmin) – ThromboGenics/ Novartis

4.9.1 Jetrea: Recent Sales Performance

4.9.2 Clinical Study Plans for Jetrea

4.9.3 Jetrea: Sales Forecast 2017-2028

4.9.4 Possible Acquisition Move on ThromboGenics

4.9.5 R&D Agreements with Eleven Biotherapeutics and Bicycle Therapeutics

4.10 Other Retinal Disorder Drugs

4.10.1 Iluvien (fluocinolone implant) – Alimera Sciences

4.10.2 Ozurdex (dexamethasone implant) – Allergan

4.10.3 Other Retinal Disorder Drugs: Sales Forecast 2017-2028

5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis and Forecast 2017-2028

5.1 Leading Products in The Allergic, Inflammatory and Infective Drugs Market, 2017

5.2 Allergic, Inflammatory and Infective Drugs: Market Trends and Developments, 2017

5.2.1 The Growth Prospects for Allergic, Inflammatory and Infective Drugs

5.2.2 Topical NSAIDs Launched: Prolensa and Ilevro

5.3 Allergic, Inflammatory and Infective Drugs: Market Forecast 2017-2028

5.3.1 Allergic, Inflammatory and Infective Drugs: Changing Market Shares by Leading Drugs 2017-2028

5.4 Leading Drugs for The Treatment of Allergic, Inflammatory and Infective Ophthalmic Conditions

5.5 Patanol And Pataday (olopatadine) – Alcon (Novartis)

5.5.1 Pataday: Sales Forecast 2017-2028

5.5.2 Impending Generic Competition for Patanol And Pataday

5.5.3 Approval of Pazeo Solution

5.5.4 Patanol: Sales Forecast 2017-2028

5.6 Vigamox (moxifloxacin) – Alcon (Novartis)

5.6.1 Intensifying Competition and Generics Drug Challenge to Vigamox

5.6.2 Moxeza: A Next-Generation Form of Vigamox

5.6.3 Vigamox: Sales Forecast 2017-2028

5.7 TobraDex (tobramycin/dexamethasone) – Alcon (Novartis)

5.7.1 The Development and Commercialisation of TobraDex ST

5.7.2 TobraDex: Sales Forecast 2017-2028

5.8 Cravit (levofloxacin) – Santen

5.8.1 Cravit: Sales Forecast 2017-2028

5.9 Acular (ketorolac) – Allergan (Actavis)

5.9.1 Acular: Sales Forecast 2017-2028

5.10 AzaSite (azithromycin) – Akorn

5.10.1 AzaSite: Sales Forecast 2017-2028

5.11 Other Allergic, Inflammatory, and Infective Drugs: Sales Forecast 2017-2028

6. Glaucoma Drugs Market: Market Analysis and Forecast 2017-2028

6.1 Glaucoma Drugs: Market Overview

6.1.1 Leading Products in The Glaucoma Drugs Market, 2017

6.2 Glaucoma Drugs: Market Trends and Developments, 2017

6.2.1 Patent Expiration: A Major Restraint for Glaucoma Drugs

6.2.2 Preservative-Free Formulation Trends

6.2.3 Innovation in Treatments for Glaucoma

6.3 Simbrinza: First Beta-Blocker-Free Combination

6.4 Glaucoma Drugs: Market Forecast 2017-2028

6.4.1 Glaucoma Drugs: Changing Market Shares by Leading Drugs 2017-2028

6.5 Leading Drugs for The Treatment of Glaucoma

6.6 Lumigan And Ganfort (bimatoprost) – Allergan (Actavis)

6.6.1 Lumigan And Ganfort: Sales Forecast 2017-2028

6.7 Xalatan And Xalacom (latanoprost) – Pfizer

6.7.1 Xalatan/Xalacom: Sales Forecast 2017-2028

6.8 Travatan/Travatan Z and DuoTrav (travoprost) – Novartis

6.8.1 Travatan/Travatan Z and DuoTrav: Sales Forecast 2017-2028

6.9 Alphagan/Alphagan P and Combigan (brimonidine) – Allergan

6.9.1 Alphagan/Alphagan P and Combigan: Sales Forecast 2017-2028

6.10 Trusopt And Cosopt/Cosopt PF (dorzolamide) – Merck/ Santen

6.10.1 Divestment Agreement with Santen And Akorn

6.10.2 Trusopt: Sales Forecast 2017-2028

6.10.3 Cosopt And Cosopt PF: Sales Forecast 2017-2028

6.11 Azopt (brinzolamide) – Novartis

6.11.1 Azopt: Sales Forecast 2017-2028

6.12 Tapros (tafluprost) – Santen

6.12.1 Tapros: Sales Forecast 2017-2028

6.13 Zioptan (tafluprost) – Akorn

6.13.1 Zioptan: Sales Forecast 2017-2028

6.14 Other Glaucoma Drugs: Sales Forecast 2017-2028

7. Dry Eye Drugs Market: Market Analysis and Forecast 2017-2028

7.1 Dry Eye Drugs: Market Overview

7.1.1 Leading Products in The Dry Eye Drugs Market, 2017

7.2 Dry Eye Drugs: Market Trends and Developments, 2016

7.2.1 Restasis: Patent Elongations and Generic Challenges Creating Uncertainty

7.2.2 Intensifying Research Focused on Dry Eye

7.2.3 Improving Diagnostic Tools

7.3 Dry Eye Drugs: Market Forecast 2017-2028

7.3.1 Dry Eye Drugs: Changing Market Shares by Leading Drugs 2017-2028

7.4 Leading Drugs for The Treatment of Dry Eye

7.5 Restasis (ciclosporin) – Allergan (Actavis)

7.5.1 Restasis – Generic launch in 2016?

7.5.2 Restasis: Sales Forecast 2017-2028

7.6 Refresh Brand Products – Allergan (Actavis)

7.6.1 Refresh Brand Products: Sales Forecast 2017-2028

7.7 Hyalein (hyaluronic acid) – Santen

7.7.1 Hyalein: Sales Forecast 2017-2028

7.8 Diquas (diaquafosol) – Santen

7.8.1 Diquas: Sales Forecast 2017-2028

7.9 Other Dry Eye Drugs: Sales Forecast 2017-2028

7.10 Other Ophthalmic Drugs

7.10.1 Hetlioz (tasimelteon) – Vanda Pharmaceuticals

7.10.2 Hetlioz: Sales Forecast 2017-2028

8. Leading National Markets for Ophthalmic Drugs, 2017-2028

8.1 The Ophthalmic Drugs Market by Region

8.1.1 The Global Distribution of Ophthalmic Drugs In 2017

8.2 Leading National Markets: Forecast 2017-2028

8.2.1 Changing Market Shares by Region, 2017-2028

8.3 Regional Ophthalmic Drugs Markets: Analysis and Forecasts, 2017-2028

8.4 United States: The Largest Ophthalmic Drugs Market

8.4.1 How Will the Rise of a Biosimilars Market Impact on US Ophthalmic Drugs?

8.4.2 US Ophthalmic Drugs Market: Market Forecast 2017-2028

8.5 EU5

8.5.1 EU5 Ophthalmic Drugs Market: Market Forecast 2017-2028

8.5.1.1 EU5 Markets: Changing Market Shares by Country, 2017-2028

8.5.2 Germany

8.5.2.1 German Ophthalmic Drugs Market: Market Forecast 2017-2028

8.5.3 France

8.5.3.1 French Ophthalmic Drugs Market: Market Forecast 2017-2028

8.5.4 UK

8.5.4.1 UK Ophthalmic Drugs Market: Market Forecast 2017-2028

8.5.4.2 Brexit – Increased Uncertainty May Affect the UK Ophthalmic Drug Market

8.5.5 Italy

8.5.5.1 Italian Ophthalmic Drugs Market: Market Forecast 2017-2028

8.5.6 Spain

8.5.6.1 Spanish Ophthalmic Drugs Market: Market Forecast 2017-2028

8.6 Japan

8.6.1 The Cost of Treatment in Japan

8.6.2 Japanese Pharmaceutical Industry Regulatory Reform

8.6.3 Japanese Ophthalmic Drugs Market Forecast 2017-2028

8.7 China

8.7.1 Expansion of Healthcare Coverage and Reimbursement in China

8.7.2 Price Controls and The Anhui Model

8.7.3 Chinese Ophthalmic Drugs Market: Market Forecast 2017-2028

8.8 Brazil

8.8.1 How Will Brazil’s Growing Healthcare Influence Ophthalmic Drugs

8.8.2 Brazilian Ophthalmic Drugs Market: Market Forecast 2017-2028

8.9 Russia

8.9.1 How Will Russia’s Economic Status Affect Its Pharma Industry?

8.9.2 Russian Ophthalmic Drugs Market: Market Forecast 2017-2028

8.10 India

8.10.1 The Impact of The Drug Prices Control Order on Indian Pharma

8.10.2 India’s Expansion of Healthcare Provision

8.10.3 Indian Ophthalmic Drugs Market: Market Forecast 2017-2028

8.11 Rest of the World

8.11.1 Rest of the World Ophthalmic Drugs Market: Market Forecast 2017-2028

9. Leading Companies in the Ophthalmic Drugs Market, 2017-2028

9.1 Ophthalmic Drugs – A Changing Market Landscape

9.2 Leading Companies in The Ophthalmic Drugs Market, 2017

9.2.1 Ophthalmic Drugs Market: Leading Companies Forecast 2017-2028

9.2.2 Ophthalmic Drugs: Changing Market Shares by Leading Companies 2017-2028

9.3 Novartis (Alcon)

9.3.1 Novartis: Ophthalmic Drugs Portfolio, 2016

9.3.2 Novartis: Sales Forecast 2017-2028

9.3.3 Novartis: Ophthalmic Drugs Development Pipeline, 2016

9.3.4 Novartis: Recent Developments

9.3.4.1 Novartis Restructures Following Strategic Review

9.3.4.2 Novartis Licenses Ophthotech’s Fovista

9.4 Regeneron

9.4.1 Regeneron: Ophthalmic Drugs Portfolio, 2016

9.4.2 Regeneron: Recent Developments

9.4.2.1 Expanding Indications for Eylea

9.4.2.2 Eylea/Zaltrap and the Davis-Smyth Patent Agreements

9.4.3 Regeneron: Sales Forecast 2017-2028

9.4.4 Regeneron: Ophthalmic Drugs Development Pipeline, 2016

9.5 Allergan (Actavis)

9.5.1 Allergan: Ophthalmic Drugs Portfolio

9.5.2 Allergan: Recent Developments

9.5.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema

9.5.2.2 How Real Is the Threat of Generic Restasis?

9.5.2.3 Valeant’s Attempted Takeover Squashed by Actavis Bid

9.5.3 New acqusitions for healthcare development

9.5.4 Allergan: Sales Forecast 2017-2028

9.5.5 Allergan: Ophthalmic Drugs Development Pipeline, 2017

9.6 Roche

9.6.1 Roche: Ophthalmic Drugs Portfolio, 2016

9.6.1.1 Lucentis: US Sales Forecast 2017-2028

9.6.2 Roche: Sales Forecast 2017-2028

9.6.3 Roche: Ophthalmic Drugs Development Pipeline, 2016

9.7 Valeant

9.7.1 Valeant: Ophthalmic Drugs Portfolio, 2015

9.7.2 Valeant: Recent Developments

9.7.2.1 Valeant’s Acquisition of Bausch and Lomb Still Driving Its Ophthalmic Portfolio

9.7.3 Valeant: Sales Forecast 2017-2028

9.7.4 Valeant: Ophthalmic Drugs Development Pipeline, 2016

9.7.5 Valeant: Difficult End to 2015 as well as 2016 Leads to Uncertainty About Company Future

9.8 Santen

9.8.1 Santen: Ophthalmic Drugs Portfolio, 2016

9.8.2 Santen: Recent Developments

9.8.2.1 Santen Acquires Novagali Pharma

9.8.2.2 Santen Acquires Merck’s Ophthalmic Drugs Portfolio

9.8.3 Santen: Sales Forecast 2017-2028

9.8.4 Santen: Ophthalmic Drugs Development Pipeline, 2016

9.9 Bayer

9.9.1 Bayer: Ophthalmic Drugs Portfolio

9.9.2 Bayer: Sales Forecast 2017-2028

9.10 Pfizer

9.10.1 Pfizer: Ophthalmic Drugs Portfolio, 2017

9.10.1.1 Xalatan/Xalacom – Pfizer’s Leading Ophthalmic Products

9.10.1.2 Macugen – Valeant/Pfizer

9.10.2 Pfizer: Recent Developments

9.10.2.1 Pfizer Attempts to Acquire AstraZeneca

9.10.2.2 Pfizer Attempts Merger with Allergan

9.10.3 Pfizer: Sales Forecast 2017-2028

9.10.4 Pfizer: Ophthalmic Drugs Development Pipeline, 2017

9.11 Senju

9.11.1 Senju: Ophthalmic Drugs Portfolio

9.11.2 Senju: Sales Forecast 2017-2028

9.11.3 Senju: Ophthalmic Drugs Development Pipeline, 2016

9.11.3.1 Y 39983 (SNJ 1656)

9.11.3.2 Difluprednate (SJE-2079)


10. Ophthalmic Drugs: Research and Development Pipeline, 2017-2028

10.1 The Ophthalmic Drugs Pipeline: Intensive Development Efforts in Retinal Disorders

10.2 Drugs for Retinal Disorders: Development Pipeline, 2016

10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?

10.3 Retinal Disorders: Filed or Recently Launched

10.3.1 CompaqSipp (conbercept) – Chengdu Kanghong Pharmaceutical

10.3.2 Lipidil (fenofibrate) - Abbott

10.3.3 Iluvien (fluocinolone) – AlimeraSciences

10.4 Drugs in Phase 3 Development For Retinal Disorders

10.4.1 AGN150998 And MP0260 (Anti-VEGFDARPins) - Allergan

10.4.2 Fovista and Zimura – Ophthotech Corporation

10.4.3 Lampalizumab (anti-FactorD Fab) - Roche

10.4.4 MC-1101 (hydralazine) – Macu CLEAR

10.4.5 Squalamine (anti-angiogenic drug) - OHRPharmaceutical

10.4.6 Tandospirone (serotonin 1A agonist) – Alcon (Novartis)

10.4.7 UF-021 (unoprostone) - R-TechUeno

10.5 Drugs in Phase 2 Development for Retinal Disorders

10.5.1 AKB-9778 (Tie2 activator) - AerpioTherapeutics

10.5.2 Luminate (ALG-1001; Integrin peptide therapy) - Allegro/Senju

10.5.3 AGN208397 (beclomethasone) - Allergan

10.5.4 CPC 551 - ColbyPharmaceutical

10.5.5 ESBA1008 (anti-VEGF mAb) – Alcon (Novartis)

10.5.6 iCo-007 (antisense inhibitor of C-raf kinase mRNA) - iCo Therapeutics

10.5.7 LFG316 (anti-C5 mAb) - Novartis

10.5.8 Intravitreal brimonidine implant - Allergan

10.5.9 Optina (danazol) - AmpioPharmaceuticals

10.5.10 PF-655 (synthetic siRNA) - Quark/Pfizer

10.5.11 Premiplex (SHP-607) - Shire

10.5.12 Renexus (ciliary neurotrophic factor) - Neurotech

10.5.13 Zybrestat (fosbretabulin) - Oxigene/SymphonyVIDA

10.6 DrugsInPhase 1 and Pre-clinical Developmentfor RetinalDisorders

10.6.1 BDM-E - BioDiem

10.6.2 NADPHOxidaseInhibitors – AlimeraSciences

10.6.3 PAN-90806 (topical VEGF inhibitor) - PanOptica

10.6.4 PlasmaKallikreinInhibitors (KVD001) - KalVista

10.6.5 QLT091001 (synthetic retinoid) – QLT

10.7 Drugs in Phase 3 Development for Allergic, Inflammatory and Infective Ophthalmic Conditions

10.7.1 EGP-437 (dexamethasone) – EyeGatePharmaceuticals

10.7.2 IBI-10090 and IBI-20089 - IconBioscience

10.7.3 KPI-121 (loteprednol etabonate) - Kala

10.8 Drugs in Phase 2 Development for Allergic, Inflammatory and Infective Ophthalmic Conditions

10.8.1 CF101 (adenosine A3 receptor agonist) - Can-FiteBioPharma and OphthaliX

10.8.2 FST-100 (povidone-iodine/dexamethasone) - Shire

10.8.3 NVC-422 (auriclosene) - NovaBay

10.8.4 Sarilumab - Regeneron

10.9 Drugs in Phase 1 And Pre-clinical Development for Allergic, Inflammatory and Infective Ophthalmic Conditions

10.9.1 Finafloxacin - MerLionPharmaceuticals/Novartis

10.10 Drugs for Glaucoma: Development Pipeline, 2016

10.11 Drugs in Phase 2&3 Development for Glaucoma

10.11.1 Latanoprostene Bunod (VESNEO; BOL 303259-X) - Valeant

10.11.2 AMA0076 (ROCK inhibitor) - Amakem

10.11.3 Rhopressa (AR-13324; ROCK and NET inhibitor) AndRoclatan (PG324; ROCK inhibitor) – Aerie Pharmaceuticals

10.12 Drugs in Phase 1 And Pre-clinical Development for Glaucoma

10.13 Drugs in Phase 3 Development for Dry Eye

10.13.1 EBI-005 (IL-1R antagonist) – Eleven Biotherapeutics

10.13.2 Lifitegrast (integrin antagonist) - Shire

10.13.3 Tavilermide (formerly MIM-D3tyrosine kinase receptor antagonist) - Allergan

10.13.4 SI-614 (modified hyaluronate) - Seikagaku

10.14 Drugs in Phase 2 Development for Dry Eye

10.14.1 ESBA105 (TNF-alpha antibody) - Alcon (Novartis)

10.14.2 Kineret (anakinra: IL-1 receptor antagonist) - Amgen/Sobi

10.15 Other Drugs in the Development Pipeline for Ophthalmic Conditions

10.15.1 Brimonidine For Eye Whitening - Valeant

10.15.2 GS-101 (aganirsen) - GeneSignal

10.15.3 Omidria (phenylephrine/ketorolac) – Omeros


11. Qualitative Analysis of the Ophthalmic Drugs Market, 2017-2028

11.1 Market Factors Influencing Ophthalmic Drugs

11.2 SWOT Analysis of the Global Ophthalmic Drugs Market, 2017-2028

11.3 Strengths

11.3.1 A Healthy R&D Pipeline

11.3.2 Advances in Drug Delivery Technologies

11.3.3 Support for Reimbursement and Payment Approvals

11.3.4 Gene Therapy and RNAi Technology

11.3.5 New Ophthalmic Therapeutic Applications for Drugs

11.3.6 Development of Neuroprotective Anti-Glaucoma Medications

11.3.7 Biomarkers as Tools for Better Diagnosis and Treatment

11.4 Weaknesses

11.4.1 Low Levels of Patient Adherence to Treatment

11.4.2 High Treatment Burden on Patients and Healthcare Providers

11.4.3 Under-Diagnosis and Under-Treatment

11.5 Opportunities

11.5.1 Sustained-Release Ocular Implants

11.5.2 The Impact of a Rapidly Ageing Global Population

11.5.3 Increasing Prevalence of Diabetes and Ocular Disease

11.5.4 Glaucoma and Retinal Disorders Set for Most-Marked Increases in Prevalence

11.5.5 Unmet Clinical Need in Many Disease Areas

11.5.6 Economic Growth in Emerging Market Provide Opportunity for Expansion

11.6 Threats

11.6.1 Intensifying Price Regulation in The Market

11.6.2 Generic Competition – Likely to Cause Erosion of Sales for Market Leading Brands

11.6.3 Rising Cost Of R&D

11.6.4 Biosimilars – A Bigger Threat than Generics?

11.7 Porter’s Five Force Analysis of The Global Ophthalmic Drugs Market, 2017-2028

11.7.1 Threat of New Entrants

11.7.2 Rivalry Among Competitors

11.7.3 Power of Suppliers

11.7.4 Threat of Substitutes

11.7.5 Power of Buyers


12. Conclusions

12.1 Overview of Current Market Conditions and Market Forecast, 2017-2028

12.2 Leading Sectors in Ophthalmic Drugs In 2017

12.3 Leading Regions in the Ophthalmic Drugs Market In 2017

12.4 Leading Companies in The Ophthalmic Drugs Market, 2017

12.5 What Does the Future Hold for Ophthalmic Drugs?


Appendices

Associated Report

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form


List of Tables

Table 2.2 Main Classes of the Glaucoma Drugs, 2016

Table 2.3 Drug Treatments for Age-Related Macular Degeneration, 2017

Table 2.4 Drug Treatments for Ocular Allergy, 2016

Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2017

Table 2.6 Drug Treatments for Eye Infections, 2017

Table 2.7 Clinical Trial Phases, 2016

Table 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2017

Table 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2017-2028

Table 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2017-2022, 2022-2028, 2017-2028

Table 3.4 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Sector, 2017, 2022, 2028

Table 4.1 Top Drugs in The Retinal Disorder Drugs Market: Revenue ($m) and Market Shares (%), 2017

Table 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2017-2028

Table 4.3 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2017, 2022, 2028

Table 4.4 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m), AGR (%) and CAGR (%), 2017-2028

Table 4.5 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 4.6 Avastin: Ophthalmic Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 4.7 Visudyne: Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 4.8 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 4.9 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 5.1 Leading Drugs in The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m) and Market Shares (%), 2017

Table 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2017-2028

Table 5.3 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2017, 2022, 2028

Table 5.4 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 5.5 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 5.6 Vigamox: Novartis Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 5.7 TobraDex: Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 5.8 Cravit: Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 5.9 Acular: Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 5.10 AzaSite: Akorn Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 6.1 Leading Glaucoma Drugs: Revenues ($m) and Market Shares (%), 2017

Table 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2017-2028

Table 6.3 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2017, 2022, 2028

Table 6.4 Lumigan and Ganfort: Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 6.5 Xalatan/Xalacom: Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 6.6 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 6.7 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 6.8 Trusopt: Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 6.9 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 6.10 Azopt: Novartis Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 6.11 Tapros: Santen Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 6.12 Zioptan: Akorn Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 6.13 Other Glaucoma Drugs: Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 7.1 Leading Dry Eye Drugs: Revenues ($m) and Market Shares (%), 2017

Table 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2017-2028

Table 7.3 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2017, 2022, 2028

Table 7.4 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 7.5 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 7.6 Hyalein: Santen Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 7.7 Diquas: Santen Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 7.8 Other Dry Eye Drugs: Sales Forecast ($m, AGR%), 2017-2028

Table 7.9 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Table 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) and Market Share (%) by Region, 2016

Table 8.2 Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2017-2028

Table 8.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2017-2022, 2022-2028, and 2017-2028

Table 8.4 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2017, 2022, and 2028

Table 8.5 The US Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2028

Table 8.6 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2028

Table 8.7 The EU5 Ophthalmic Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2017-2028

Table 8.8 The EU5 Ophthalmic Drugs Market: Revenue ($m), and Market Share (%) by Country, 2016

Table 8.9 The EU5 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2028

Table 8.10 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2016, 2021, 2027

Table 8.11 The German Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2028

Table 8.12 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2028

Table 8.13 The French Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2028

Table 8.14 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2028

Table 8.15 The UK Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2028

Table 8.16 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2028

Table 8.17 The Italian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2028

Table 8.18 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2028

Table 8.19 The Spanish Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2028

Table 8.20 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2028

Table 8.21 The Japanese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2028

Table 8.22 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2028

Table 8.23 The Chinese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2028

Table 8.24 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2028

Table 8.25 The Brazilian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2028

Table 8.26 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2028

Table 8.27 The Russian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2028

Table 8.28 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2028

Table 8.29 The Indian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2027

Table 8.30 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2028

Table 8.31 The Rest of the World Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2028

Table 8.32 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2028

Table 9.1 Leading Ophthalmic Drug Companies: Revenues ($m) and Market Shares (%), 2017

Table 9.2 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Companies, 2017-2028

Table 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2017, 2022, 2028

Table 9.4 Novartis: Company Overview, 2016

Table 9.5 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2028

Table 9.6 Regeneron: Company Overview, 2016

Table 9.7 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2028

Table 9.8 Allergan: Company Overview, 2016

Table 9.9 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2028

Table 9.10 Roche: Company Overview, 2016

Table 9.11 Lucentis (Roche): US Revenue Forecast ($m, AGR%, CAGR%), 2017-2028

Table 9.12 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2028

Table 9.13 Valeant: Company Overview, 2016

Table 9.14 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2028

Table 9.15 Santen: Company Overview, 2016

Table 9.16 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2028

Table 9.17 Bayer: Company Overview, 2016

Table 9.18 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2028

Table 9.19 Pfizer: Company Overview, 2016

Table 9.20 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2028

Table 9.21 Senju: Company Overview, 2016

Table 9.22 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2028

Table 10.1 RetinalDisordersDrugsPipeline: Phase 3 Drugs, 2016

Table 10.2 RetinalDisordersDrugsPipeline: Phase 2 Drugs, 2016

Table 10.3 RetinalDisordersDrugsPipeline: Phase 1 and Pre-clinical Drugs, 2016

Table 10.4 Allergic, Inflammatory and InfectiveDrugsPipeline: Phase 3 Drugs, 2016

Table 10.5 Allergic, Inflammatory and InfectiveDrugsPipeline: Phase 2Drugs, 2016

Table 10.6 Allergic, Inflammatory and InfectiveDrugsPipeline: Phase 1 and Pre-clinical Drugs, 2016

Table 10.7 GlaucomaDrugsPipeline: Phase 2&3 Drugs, 2016

Table 10.8 GlaucomaDrugsPipeline: Phase 1 and Pre-clinical Drugs, 2016

Table 10.9 DryEyeDrugsPipeline: Phase 3 Drugs, 2016

Table 10.10 DryEyeDrugsPipeline: Phase 2 Drugs, 2016

Table 10.11OtherPipelineProducts for OphthalmicConditions, 2016

Table 11.1 SWOT Analysis of the Global Ophthalmic Drugs Market, 2017-2028

Table 11.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2017-2028

Table 11.3 Global Prevalence Forecast for Ophthalmic Diseases

Table 12.1 Global Ophthalmic Drugs: Market Forecast ($m, CAGR%), 2017, 2022 and 2028

Table 12.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2016, 2021, 2027

Table 12.2 Top ten ophthalmic drug companies in 2017


List of Figures

Figure 1.1 Global Ophthalmic Drugs Market: Market Sectors, 2017

Figure 2.1 Structure of The Human Eye

Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2014

Figure 2.3 Global Causes of Visual Impairment (% of cases), 2012

Figure 2.4 Classification of Glaucoma, 2016

Figure 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) by Sector, 2017

Figure 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2017-2022

Figure 3.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2022-2028

Figure 3.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2017-2028

Figure 3.6 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2017

Figure 3.7 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2022

Figure 3.8 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2028

Figure 4.1 Top Drugs in The Retinal Disorder Drugs Market: Revenue ($m), 2017

Figure 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 4.3 Retinal Disorder Drugs Market: Revenue Forecast ($m, AGR%) by Leading Drugs, 2017-2028

Figure 4.4 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2016

Figure 4.5 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2022

Figure 4.6 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2028

Figure 4.7 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m, AGR%), 2017-2028

Figure 4.8 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%), 2017-2028

Figure 4.9 Avastin: Ophthalmic Sales Forecast ($m, AGR%), 2017-2028

Figure 4.10 Visudyne: Sales Forecast ($m, AGR%), 2017-2028

Figure 4.11 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%), 2017-2028

Figure 4.12 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%), 2017-2028

Figure 5.1 Leading Drugs in The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m), 2017

Figure 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 5.3 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2017-2028

Figure 5.4 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2017

Figure 5.5 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2021

Figure 5.6 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2027

Figure 5.7 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2017-2028

Figure 5.8 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2017-2028

Figure 5.9 Vigamox: Novartis Sales Forecast ($m, AGR%), 2017-2028

Figure 5.10 TobraDex: Sales Forecast ($m, AGR%), 2017-2028

Figure 5.11 Cravit: Sales Forecast ($m, AGR%), 2017-2028

Figure 5.12 Acular: Sales Forecast ($m, AGR%), 2017-2028

Figure 5.13 AzaSite: Akorn Sales Forecast ($m, AGR%), 2017-2028

Figure 5.14 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%), 2017-2028

Figure 6.1 Leading Glaucoma Drugs: Revenue ($m), 2017

Figure 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 6.3 Glaucoma Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2017-2028

Figure 6.4 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2017

Figure 6.5 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2022

Figure 6.6 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2028

Figure 6.7 Lumigan and Ganfort: Sales Forecast ($m, AGR%), 2017-2028

Figure 6.8 Xalatan/Xalacom: Sales Forecast ($m, AGR%), 2017-2028

Figure 6.9 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%), 2017-2028

Figure 6.10 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%), 2017-2028

Figure 6.11 Trusopt: Merck/Santen Sales Forecast ($m, AGR%), 2017-2028

Figure 6.12 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%), 2017-2028

Figure 6.13 Azopt: Novartis Sales Forecast ($m, AGR%), 2017-2028

Figure 6.14 Tapros: Santen Sales Forecast ($m, AGR%), 2017-2028

Figure 6.15 Zioptan: Akorn Sales Forecast ($m, AGR%), 2017-2028

Figure 6.16 Other Glaucoma Drugs: Sales Forecast ($m, AGR%), 2017-2028

Figure 7.1 Leading Dry Eye Drugs: Revenue ($m), 2017

Figure 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 7.3 Dry Eye Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2017-2028

Figure 7.4 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2017

Figure 7.5 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2022

Figure 7.6 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2028

Figure 7.7 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%), 2017-2028

Figure 7.8 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%), 2017-2028

Figure 7.9 Hyalein: Santen Sales Forecast ($m, AGR%), 2017-2028

Figure 7.10 Diquas: Santen Sales Forecast ($m, AGR%), 2017-2028

Figure 7.11 Other Dry Eye Drugs: Sales Forecast ($m, AGR%, CAGR%), 2017-2028

Figure 7.12 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%), 2017-2028

Figure 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) by Region, 2016

Figure 8.2 US, EU5, China and Japan Ophthalmic Drugs Market: Market Forecast ($m), 2017-2028

Figure 8.3 Brazil, Russia and India Ophthalmic Drugs Market: Market Forecast ($m), 2017-2028

Figure 8.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2017-2022

Figure 8.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2022-2028

Figure 8.6 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2017-2028

Figure 8.7 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2017

Figure 8.8 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2021

Figure 8.9 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2027

Figure 8.10 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 8.11 The EU5 Ophthalmic Drugs Market: Revenue ($m) by Country, 2016

Figure 8.12 Germany, France, UK, Italy, and Spain Ophthalmic Drugs Market: Market Forecast ($m), 2017-2028

Figure 8.13 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2017

Figure 8.14 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2022

Figure 8.15 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2028

Figure 8.16 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 8.17 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 8.18 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 8.19 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 8.20 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 8.21 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 8.22 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 8.23 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 8.24 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 8.25 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 8.26 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2028

Figure 9.1 Leading Ophthalmic Drug Companies: Revenue ($m), 2017

Figure 9.2 Ophthalmic Drugs Market: Market Forecast ($m) by Leading Companies, 2017-2028

Figure 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2016

Figure 9.4 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2021

Figure 9.5 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2027

Figure 9.6 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2017-2028

Figure 9.7 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2017-2028

Figure 9.8 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2017-2028

Figure 9.9 Lucentis (Roche): US Revenue Forecast ($m, AGR%), 2017-2028

Figure 9.10 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2017-2028

Figure 9.11 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2017-2028

Figure 9.12 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2017-2028

Figure 9.13 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2017-2028

Figure 9.14 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2017-2028

Figure 9.15 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2017-2028

Figure 11.1 World 65+ Population Forecast: Size (m), AGR (%), 2017-2028

Figure 11.2 Global Prevalence of Diabetes and Diabetic Retinopathy, 2010 and 2030

Figure 11.3 Porter’s Five Force Analysis of the Ophthalmic Drugs Market, 2017

Figure 12.1 Global Ophthalmic Drugs: Market Forecast ($m), 2017- 2028

Figure 12.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2017-2028

★調査レポート[過活動膀胱治療の世界市場] ( Global Overactive Bladder Treatment Market 2018-2028 / VGN808053) 販売に関する免責事項
[過活動膀胱治療の世界市場] ( Global Overactive Bladder Treatment Market 2018-2028 / VGN808053) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆